A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)
Phase: PHASE3 | Sponsor: Usona Institute | Compound: Psilocybin
- Status
- active
- Institution
- Usona Institute
- Start date
- 2024-03-13
- End date
- 2026-12-30
- Registry ID
- NCT06308653
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.